Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Buy
70
ALLO Quote, Financials, Valuation and Earnings
Last price:
$2.07
Seasonality move
:
-11.41%
Day range:
$2.06 - $2.30
52-week range:
$0.86 - $2.64
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
2,442.58x
P/B ratio:
1.52x
Volume:
5.9M
Avg. volume:
6.4M
1-year change:
-18.08%
Market cap:
$478.7M
Revenue:
$22K
EPS (TTM):
-$0.98
Analysts' Opinion
-
Consensus RatingAllogene Therapeutics, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 10 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $7.38, Allogene Therapeutics, Inc. has an estimated upside of 246.64% from its current price of $2.13.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $1.60 representing 100% downside risk from its current price of $2.13.
Fair Value
-
According to the consensus of 11 analysts, Allogene Therapeutics, Inc. has 246.64% upside to fair value with a price target of $7.38 per share.
ALLO vs. S&P 500
-
Over the past 5 trading days, Allogene Therapeutics, Inc. has overperformed the S&P 500 by 28.61% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Allogene Therapeutics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Allogene Therapeutics, Inc. revenues have been falling on a year-over-year basis for 10 quarters in a row. In the most recent quarter Allogene Therapeutics, Inc. reported revenues of --.
Earnings Growth
-
Allogene Therapeutics, Inc. has grown year-over-year earnings for 9 quarters straight. In the most recent quarter Allogene Therapeutics, Inc. reported earnings per share of -$0.19.
Enterprise value:
311.6M
EV / Invested capital:
--
Price / LTM sales:
2,442.58x
EV / EBIT:
--
EV / Revenue:
-629.31x
PEG ratio (5yr expected):
-0.52x
EV / Free cash flow:
-1.96x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$12.5M
Return On Assets:
-41.47%
Net Income Margin (TTM):
-335973.56%
Return On Equity:
-54.89%
Return On Invested Capital:
-44.62%
Operating Margin:
-315927.27%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $121K | $43K | -- | -- | -- | |
| Gross Profit | -$13.9M | -$13.8M | -$12.5M | -$3.2M | -$3.1M | |
| Operating Income | -$339M | -$268.9M | -$225M | -$61M | -$44.9M | |
| EBITDA | -$325M | -$255M | -$212.5M | -$57.8M | -$41.8M | |
| Diluted EPS | -$2.26 | -$1.56 | -$0.98 | -$0.32 | -$0.19 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $502.9M | $569.1M | $473.5M | $304.4M | $260.7M | |
| Total Assets | $1.1B | $887.6M | $712.3M | $589.1M | $439.8M | |
| Current Liabilities | $53.5M | $48.9M | $37.6M | $32.6M | $31.8M | |
| Total Liabilities | $109.3M | $147.6M | $129.2M | $125.4M | $124.4M | |
| Total Equity | $969.9M | $740M | $583.1M | $463.7M | $315.3M | |
| Total Debt | $53.9M | $96.7M | $90.1M | $85.1M | $77.1M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$246.1M | -$217.3M | -$158.3M | -$44.1M | -$29.7M | |
| Cash From Investing | $145.4M | $88.2M | $116.9M | -$76M | $11.9M | |
| Cash From Financing | $95.6M | $111.1M | $28M | $679K | $3.2M | |
| Free Cash Flow | -$249.1M | -$217.9M | -$159M | -$44.5M | -$29.9M | |
ALLO
Sector
Market Cap
$478.7M
$25.2M
Price % of 52-Week High
80.71%
49.83%
Dividend Yield
0%
0%
Shareholder Yield
-6.98%
-1.77%
1-Year Price Total Return
-18.08%
-21.9%
Beta (5-Year)
0.603
0.499
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$1.88
200-day SMA
Buy
Level
$1.32
Bollinger Bands (100)
Buy
Level
1.2 - 1.66
Chaikin Money Flow
Sell
Level
-127.7M
20-day SMA
Buy
Level
$1.76
Relative Strength Index (RSI14)
Buy
Level
64.80
ADX Line
Buy
Level
32.07
Williams %R
Neutral
Level
-22.3684
50-day SMA
Buy
Level
$1.60
MACD (12, 26)
Buy
Level
0.13
25-day Aroon Oscillator
Buy
Level
60
On Balance Volume
Neutral
Level
107.6M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-3.4625)
Sell
CA Score
(Annual)
Level (-1.1094)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (3.2806)
Sell
Piotroski F Score
(Annual)
Level (3)
Sell
Quality Ratio Score
Level (1)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The firm develops a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells. Its engineered T cells are allogeneic, which are derived from healthy donors for intended use in any patient. The company was founded by Arie S. Belldegrun, David D. Chang, David M. Tanen, and Joshua A. Kazam in November 2017 and is headquartered in South San Francisco, CA.
Stock Forecast FAQ
In the current month, ALLO has received 10 Buy ratings 1 Hold ratings, and 0 Sell ratings. The ALLO average analyst price target in the past 3 months is $7.38.
-
Where Will Allogene Therapeutics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Allogene Therapeutics, Inc. share price will rise to $7.38 per share over the next 12 months.
-
What Do Analysts Say About Allogene Therapeutics, Inc.?
Analysts are divided on their view about Allogene Therapeutics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Allogene Therapeutics, Inc. is a Sell and believe this share price will drop from its current level to $1.60.
-
What Is Allogene Therapeutics, Inc.'s Price Target?
The price target for Allogene Therapeutics, Inc. over the next 1-year time period is forecast to be $7.38 according to 11 Wall Street analysts, 10 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is ALLO A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Allogene Therapeutics, Inc. is a Buy. 10 of 11 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of ALLO?
You can purchase shares of Allogene Therapeutics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Allogene Therapeutics, Inc. shares.
-
What Is The Allogene Therapeutics, Inc. Share Price Today?
Allogene Therapeutics, Inc. was last trading at $2.07 per share. This represents the most recent stock quote for Allogene Therapeutics, Inc.. Yesterday, Allogene Therapeutics, Inc. closed at $2.13 per share.
-
How To Buy Allogene Therapeutics, Inc. Stock Online?
In order to purchase Allogene Therapeutics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get ALLO Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
ALLO
Sector
P/E ratio
--
23.30x
PEG ratio
-0.52x
-0.01x
P/B ratio
1.52x
1.78x
Price / LTM sales
2,442.58x
1.55x
Growth Metrics
ALLO
Sector
Revenue growth
-26.67%
3.69%
Earnings growth
41.18%
9.95%
Revenue (5-year growth)
--
6.38%
Earnings forecast
-$0.22
-$0.19
Profitability
ALLO
Sector
Profitability FY 2024
-$13.6M
$2.6M
Return on invested capital
-44.62%
-33.25%
Return on assets
-41.47%
-29.67%
Return on equity
-54.89%
-38.66%
Earnings Date
Last Earnings Date
Nov
6
Next Earnings Date
Mar
19
Estimated Next Earnings Date
Feb
5
Balance Sheet
ALLO
Sector
Total cash
$252.2M
$25.1M
Short term investments
$217.3M
$24M
Total assets
$548.7M
$72.5M
Long term debt
$77.1M
$2.6M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Buy
56
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Sell
49
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 35x
Sell
44
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Sell
23
CAR alert for Feb 20
Avis Budget Group, Inc. [CAR] is down 0.5% over the past day.
Buy
75
HYMC alert for Feb 20
Hycroft Mining Holding Corp. [HYMC] is down 1.33% over the past day.
Sell
1
EPAM alert for Feb 20
EPAM Systems, Inc. [EPAM] is down 1.73% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
